Introduction
Super-refractory status epilepticus (super-RSE) is defined as status epilepticus that continues or recurs for 24 h or more after the onset of anesthetic therapy, including cases where status epilepticus recurs upon the reduction or withdrawal of anesthesia [1] . Super-RSE is thought to account for 15% of all status epilepticus cases. Several therapeutic approaches have been proposed for super-RSE, including immunotherapy, hypothermia, ketogenic diet, and surgery; however, there is insufficient data regarding the effectiveness, safety, and outcomes of these treatments.
New-onset refractory status epilepticus (NORSE) is a syndrome of refractory status epilepticus that manifests de novo in previously healthy patients. The characteristics of NORSE include multifocal epileptiform discharges on electroencephalography (EEG) and hyperintensities in the temporal lobe on magnetic resonance imaging (MRI). The most commonly identified cause of NORSE is autoimmune encephalitis related to the production of autoantibodies to the glutamate receptor (GluR). NORSE is generally treated with antiepileptic agents, immunological therapy, and anesthetics. However, one previous study reported that 22% of patients died and 39% experienced severe neurological complications as a result of NORSE [2] .
Vagus nerve stimulation (VNS) has been used to treat super-RSE in five previous case reports. Here, we report a case of super-RSE in a patient with NORSE who was successfully treated with VNS.
Case report
A 24-year-old man with no history of epilepsy or neurological disorders presented with delirium and shouting of meaningless words, two days after the onset of fever related to a mild upper respiratory infection. The next day (day 2), the patient developed clonic seizures on the left side of his face that sometimes evolved into generalized tonic-clonic seizures. The frequency of seizures gradually increased until they occurred every few minutes. Intravenous diazepam and phenytoin were administered to no effect. Finally, the seizures were controlled with intravenous propofol (100 mg/h). On day 3, propofol therapy was changed to midazolam (10 mg/h). An analysis of cerebrospinal fluid (CSF) revealed normal white blood cell counts and protein levels. A CSFpolymerase chain reaction test for herpes simplex virus was ) and CSF (+4 SD). Anti-GluRd2-NT antibodies were also elevated in serum (+0.7 SD) and CSF (+3.8 SD).
On day 14, the patient's seizures recurred, affecting the right side of the face and arm. High-dose thiopental (250 mg/h) was initiated, which induced a suppression-burst pattern on EEG. The patient thereafter required respiratory support with a mechanical ventilator. Thiopental dose reduction resulted in seizure recurrence despite the addition of valproate (2 g/day) and lamotrigine (200 mg/day). Immunological therapies including steroid-pulse therapy, high-dose intravenous immunoglobulin, and plasma exchange therapy were ineffective. Approximately 6 months after the onset, the dosage of intravenous midazolam was reduced to 1-2 mg/h to allow withdrawal of the mechanical ventilator; however, replacement of midazolam with intravenous valproate, zonisamide, levetiracetam, or topiramate was unsuccessful due to the reappearance of partial seizures. On day 18, brain MRI with fluid attenuation inversion recovery demonstrated hyperintensities in the bilateral temporal lobes and right insula.
At 14 months after symptom onset, the patient was transferred to our hospital for intensive treatment of refractory seizures. Upon admission, the patient was being treated with intravenous midazolam (2 mg/h), bedridden, unable to communicate verbally, and required tube feeding. Midazolam dose reduction resulted in the recurrence of seizures every ten minutes. Video EEG monitoring revealed independent seizure activity and interictal discharges in the left and right temporal lobes (Fig. 1) . MRI revealed atrophic changes in the bilateral medial temporal structures. The patient underwent an anterior 4/5 corpus callosotomy (CC) to treat secondary generalized seizures; however, oral automatism and partial tonic-clonic seizures in the bilateral face and arms persisted, occurring every 1-2 h after the surgery. Nine days after the CC, a device for VNS (VNS Therapy System, Cyberonics, Inc., Houston, TX, USA) was implanted to treat the patient's residual RSE. The current output and duty cycle of VNS were rapidly titrated ( Table 1 ). The dose of intravenous midazolam was gradually reduced and finally discontinued at 10 days after the start of VNS. At 2 months after the start of VNS, seizures had completely disappeared except for occasional eye deviation seizures. The patient was discharged from our hospital at 3 months after VNS implantation. Partial facial seizures reappeared after hospital discharge at a frequency of once per week. The patient was seizurefree at one year after implantation; the VNS parameters were 3.00 mA output current and 35% duty cycle. He had severe cognitive impairment and required wheelchair assistance.
Discussion
The rapid titration of VNS was highly effective for the treatment of RSE with NORSE in the present case. The VNS protocol typically recommends a slow titration of stimulation parameters; however, we found that increasing the output current and duty cycle every 2-4 days with careful monitoring of the patient's tolerance was ideal for seizure control in RSE. A literature review revealed that 76% of patients with generalized RSE and 25% of patients with focal RSE responded to VNS. Additionally, five previous case studies reported the successful treatment of super-RSE with VNS; all five patients received rapid titration and experienced a greater than 50% reduction in seizure frequency after implantation, regardless of seizure type or VNS parameters (Table 2) [3] [4] [5] [6] [7] . One of the case in those studies utilized VNS therapy to terminate refractory nonconvulsive status epilepticus secondary to anti-GluR encephalitis [7] . While these data alone do not support a recommendation for the use of VNS in RSE secondary to autoimmune encephalitis [8] , future prospective studies are needed for validating the therapeutic utility in the conditions. In conclusion, this is the first case to report the utility of rapid VNS titration for the treatment of super-RSE with NORSE/in the acute phase of anti-GluR encephalitis. The rapid titration of VNS to an output current of 2.5 mA allowed the immediate reduction of intensive pharmacotherapy and seizure remission at one year after implantation. VNS may therefore be a good candidate for the treatment of RSE secondary to autoimmune encephalitis.
